Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
MSD Files Silgard 9 for Male Use in Japan
MSD said on November 15 that it has filed its nine-valent HPV vaccine Silgard 9 to broaden its label into male usages in Japan. The company is seeking its approval for the new population of males nine years of age…
To read the full story
BUSINESS
- Japan’s Big 4 Drug Wholesalers Log 17.6% Operating Profit Growth
November 18, 2024
- Pfizer Japan Taps COO Hiroo Igarashi as New Skipper
November 18, 2024
- Dispensing Costs for Top LLPs Fall over 30% after Elective Care Rollout: Intage
November 18, 2024
- Shipment Curbs Growing for Strattera Generics amid Nitrosamine Issues
November 18, 2024
- MSD Files Silgard 9 for Male Use in Japan
November 18, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…